Cellevat3d® iPSC nanofiber microcarriers

Product in development, expected launch 2027

Cellevate, Fraunhofer IBMT and OLS consortium awarded EUR 1 million Eurostar grant for large scale production of induced pluripotent stem cells

Cellevate AB, Fraunhofer IBMT (Institute for Biomedical Engineering), and the German bioreactor company OLS (Omni Life Science) have been awarded a EUR 1 million grant through the Eurostar program for large scale production of iPSCs (induced pluripotent stem cells). The project will run for three years and aims to validate the use of Cellevat3d® nanofiber microcarriers for large scale production of iPSCs in the OLS bioreactor including benchmarking data vs market standard processes. Fraunhofer IBMT will play an important role in designing and performing the studies through its leading expertise in applied stem cell research and biomedical engineering, while OLS brings specialized knowhow in cutting-edge bioreactor technologies and cell culture systems.

The global iPSC market is expected to grow from USD 677 million in 2023 to USD 1.1 billion by 2030, with a CAGR of 8.8%. iPSCs are a promising cell source for curative therapies, disease modeling, and drug discovery. These cells can differentiate into a wide variety of cell types, including neurons and cardiomyocytes, which is not possible for many other cell types, such as mesenchymal stem cells (MSCs).

Cellevate Press Release, April 25, 2025

Let’s talk

Contact us through the form below to book a meeting, or ask us questions.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.